RFA-AA-23-004: Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $1.2 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on April 18, 2024.
From the official notice on Grants.gov, last changed October 17, 2023. Checked November 7, 2026.
- Award ceiling$1.2 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP60
- Clinical trialsOptional
- Funded byNIAAA
- Median yearly award$254,489
- Typical project length5 years
Projects funded under RFA-AA-23-004 were run by National Institute on Alcohol Abuse and Alcoholism (NIAAA, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AA-23-004 in the NIH Guide.
Key dates
| Posted | October 17, 2023 |
|---|---|
| Deadline | April 18, 2024 |
| Archived by Grants.gov | May 24, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $254,489; it allows up to $1.2 million per award.
- Most of the program's money (73% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) seeks applications for research center grants to conduct high-impact research on alcohol and HIV/AIDS. Through this NOFOA, NIAAA seeks to encourage research applications aimed to address the impact of alcohol use (and related other substance use, mental health, and pharmacological/medication complications) on the most important challenges for controlling and ending HIV/AIDS pandemic. This announcement reflects the high priority topics for research described in the NIH Office of AIDS Research FY2021-FY2025 Strategic Plan for HIV and HIV-Related Research https://www.oar.nih.gov/sites/default/files/NIH_StrategicPlan_FY2021-2025.pdf and research aspects included in the National HIV/AIDS Strategy (2022-2025) https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025 focused on ending the HIV epidemic among substance users (c.f. alcohol and drug). In particular, translational studies of alcohol use as a risk factor impacting HIV prevention, treatment effectiveness, and HIV-related comorbidities are strongly encouraged.
Funded under RFA-AA-23-004 so far
NIH funded 5 projects under RFA-AA-23-004 in fiscal 2025 to 2026, at 5 institutions. The median yearly award was $254,489.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| ARCH REACH Dissemination Core | University of Washington | 2026 | $86,267 |
| Alcohol, Immunosenescence, & Senodynamics in People with HIV | LSU Health Sciences Center | 2026 | $53,516 |
| AWARE Administrative and Data Analytics Core | Yale University | 2026 | $427,294 |
| Administrative Core | Vanderbilt University Medical Center | 2026 | $149,287 |
| Center for Alcohol/HIV Innovations and Biomarker Research (CALIBER) | University of California, San Francisco | 2026 | $1.5 million |
Who has won Alcohol Research Programs grants before
From fiscal 2021 to 2025, Alcohol Research Programs (93.273) awarded $2.2 billion across 2,255 grant awards, an average of $974,579 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 75 | $86.5 million |
| University of North Carolina at Chapel Hill | North Carolina | 76 | $60.7 million |
| Trustees of Indiana University | Indiana | 47 | $54.8 million |
| University of California, San Diego | California | 47 | $54.5 million |
| The Medical University of South Carolina | South Carolina | 57 | $45.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AA-23-004 still open?
No. It closed on April 18, 2024.
Who can apply for Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Comprehensive Alcohol-HIV/AIDS Research Center (P60 Clinical Trial Optional)?
Closed April 18, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.2 million each.
Who has been funded under RFA-AA-23-004?
NIH RePORTER lists 5 projects funded under RFA-AA-23-004 in fiscal 2025 to 2026, at 5 institutions. The most were at University of Washington, LSU Health Sciences Center, Yale University.
Who has won Alcohol Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, University of North Carolina at Chapel Hill, Trustees of Indiana University. The program made 2,255 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)